{
    "ticker": "ADMA",
    "name": "ADMA Biologics, Inc.",
    "description": "ADMA Biologics, Inc. is a biotechnology company focused on the development and commercialization of specialty biologics for the treatment of immune deficiencies and infectious diseases. Founded in 2004 and headquartered in Ramsey, New Jersey, ADMA is dedicated to providing innovative therapeutic options derived from human plasma. The company's lead product, ASCENIV, is an intravenous immunoglobulin (IVIG) product that is designed to treat patients with primary immunodeficiency diseases. ADMA also offers other products such as BIVIGAM, a highly purified IgG intravenous immunoglobulin, and is actively engaged in developing new therapies aimed at improving patient outcomes in the field of immunology. With a strong emphasis on quality and safety, ADMA ensures that its products meet the highest standards through rigorous testing and compliance with regulatory requirements. The company has established a robust supply chain and partnerships with leading healthcare providers to facilitate the distribution of its therapies to patients in need. ADMA\u2019s mission is to address unmet medical needs while advancing the science of immunotherapy and contributing to the overall health and well-being of patients.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Ramsey, New Jersey, USA",
    "founded": "2004",
    "website": "https://www.admabiologics.com",
    "ceo": "Adam Grossman",
    "social_media": {
        "twitter": "https://twitter.com/ADMA_Biologics",
        "linkedin": "https://www.linkedin.com/company/adma-biologics/"
    },
    "investor_relations": "https://investors.admabiologics.com",
    "key_executives": [
        {
            "name": "Adam Grossman",
            "position": "CEO"
        },
        {
            "name": "Brian Lenz",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Products",
            "products": [
                "ASCENIV",
                "BIVIGAM"
            ]
        }
    ],
    "seo": {
        "meta_title": "ADMA Biologics, Inc. | Specialty Biologics for Immune Deficiencies",
        "meta_description": "Learn about ADMA Biologics, Inc., a leader in developing specialty biologics and innovative therapies for treating immune deficiencies and infectious diseases.",
        "keywords": [
            "ADMA",
            "Biologics",
            "Immunotherapy",
            "ASCENIV",
            "BIVIGAM",
            "Primary Immunodeficiency"
        ]
    },
    "faq": [
        {
            "question": "What does ADMA Biologics specialize in?",
            "answer": "ADMA Biologics specializes in the development of specialty biologics for the treatment of immune deficiencies and infectious diseases."
        },
        {
            "question": "What is ASCENIV?",
            "answer": "ASCENIV is an intravenous immunoglobulin (IVIG) product developed by ADMA to treat patients with primary immunodeficiency diseases."
        },
        {
            "question": "Where is ADMA Biologics headquartered?",
            "answer": "ADMA Biologics is headquartered in Ramsey, New Jersey, USA."
        },
        {
            "question": "When was ADMA Biologics founded?",
            "answer": "ADMA Biologics was founded in 2004."
        }
    ],
    "competitors": [
        "IGEN",
        "KMX",
        "NVS"
    ],
    "related_stocks": [
        "AMGN",
        "ABBV",
        "GILD",
        "BMY"
    ]
}